APN-501 Series (Cleveland Clinic/Apeiron)

N/A

Report date: 2025/02/01 20:00:06

NME

Base Information

Drug NameAPN-501 Series (Cleveland Clinic/Apeiron)

Drug Alias NameSHP-1 inhibitors (Cleveland Clinic)TPI-1a4protein tyrosine phosphatase 1C inhibitors (Cleveland Clinic)protein tyrosine phosphatase SHP-1 inhibitors (Cleveland Clinic)TPI-1

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionProtein tyrosine phosphatase inhibitors

TargetsProtein tyrosine phosphatase

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustria

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesThe Cleveland Clinic Foundation

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesThe Cleveland Clinic Foundation Apeiron Biologics

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A